Nan Lin

Nan Lin

Auto-generated profile, based on publicly available information

Nan Lin

Department of Cardiology, Shandong Key Laboratory for Diagnosis and Treatment of Cardiovascular Diseases, Jining Key Laboratory of Precise Therapeutic Research of Coronary Intervention, Affiliated Hospital of Jining Medical University, 272029 Jining, Shandong, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
CGCuimei Guo
Cuimei Guo
HGHaizhu Gao
Haizhu Gao
XBXinxin Bian
Xinxin Bian
NLNan Lin
Nan Lin
LGLijun Gan
Lijun Gan
XCXueying Chen
Xueying Chen
Coronary heart disease (CHD) is associated with increased morbidity and mortality. Acute cardiovascular events frequently occur in patients with coronary artery stenoses exceeding 70%. Although coronary revascularization can significantly improve ischemic symptoms, the inflection point for reducing mortality from CHD has yet to be reached. Therefore, the prevention and treatment of mild-to-moderate coronary artery stenosis should be given significant attention to more effectively reduce the incidence and mortality of acute events from CHD. Subsequently, a stenosis of less than 70% is used to characterize the incidence of mild to moderate coronary artery stenosis. While acute cardiovascular events caused by soft plaque and plaque rupture may not have a significant impact on hemodynamics, these events are detrimental and result in increased mortality. This review summarizes the methods available for detecting mild-to-moderate coronary artery stenoses, assessing risk, and understanding the mechanisms underlying adverse events. Moreover, this review proposes intervention strategies for preventing and treating mild to moderate coronary stenosis.